Usha Menon, Professor of Gynaecological Oncology
Usha Menon is Professor of Gynaecological Oncology at the MRC Clinical Trials Unit at University College London, UK. An experienced trialist, she leads one of the largest randomised controlled trials to date – the UK Collaborative Trial of Ovarian Cancer Screening which provides the evidence base for all current ovarian cancer screening guidelines. Her research includes large cohort studies assessing screening in high risk women (UK Familial Ovarian Cancer Screening Study), exploring genetic and epidemiological risk factors (UK Ovarian Cancer Population Study), symptoms and intervals to diagnosis of cancer (International Cancer Benchmarking Partnership Module 4) and surgical morbidity (UK Gynaecological Oncology Surgical Outcomes and Complications Study). The trial biobanks with over half a million well-annotated samples and long-term follow-up, support numerous research collaborations and has resulted in a UCL spin-out company.
A major focus recently has been building clinical trials capacity and capability in India. As Adjunct Professor at the Department of Biotechnology, Translational Health Science and Technology Institute (THSTI) and Strategy Lead at the Clinical Development Services Agency, India, she is working with a number of Indian institutions to improve the academic clinical trials ecosystem. Initiatives include a clinical trials toolkit for India, common ethical review of multicentre research, an integrated research application system similar to that available in the UK and creation of a network of academic clinical research units that will drive design and conduct of academic trials led by Indian investigators.
She is an honorary consultant gynaecologist at UCLH NHS Foundation Trust, London, UK.
Jacobs IJ*, Menon U*, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomized controlled trial. Lancet. Lancet. 2016 Mar 5;387(10022):945-956. doi: 10.1016/S0140-6736(15)01224-6. Epub 2015 Dec 17.. *Joint first and corresponding.
Blyuss O, Burnell M, Ryan A, Gentry-Maharaj A, Marino I, Kalsi J, Manchanda R, Timms J, Parmar M, Skates S, Jacobs I, Zaikin A, Menon U. Comparison of longitudinal CA125 algorithms as a first line screen for ovarian cancer in the general population. Clin Cancer Res. 2018 Oct 1;24(19):4726-4733. doi: 10.1158/1078-0432.CCR-18-0208. Epub 2018 Jul 3.
Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I.Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945.
Gentry-Maharaj A, Fourkala EO, Burnell M, Ryan A, Apostolidou S, Habib M, Sharma A, Parmar M, Jacobs I, Menon U. Concordance of NationalCancer Registration with self-reported breast, bowel and lung cancer in England and Wales: a prospective cohort study within the UK Collaborative Trial of OvarianCancer Screening. Br J Cancer. Br J Cancer. 2013 Nov 26;109(11):2875-9. doi: 10.1038/bjc.2013.626.
Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M,
Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9.
- Risk prediction, screening and early detection of cancer, in particular ovarian and endometrial cancer
- Cancer Biomarkers
- Management of women at increased risk of gynaecological malignancies
- Clinical trials in screening and prevention
- Capacity and capability building in clinical trials / cohort studies
- Other conditions